Tiziana Life Sciences Announces Poster Presentation on Phase 2a BANYAN Clinical Trial of Intranasal Foralumab at ALS Nexus 2026
Tiziana Life Sciences announced a poster presentation at ALS Nexus 2026 detailing the Phase 2a BANYAN trial of intranasal foralumab for ALS. The randomized, placebo-controlled trial is currently in operational startup and aims to assess safety, biomarkers, and early clinical signals with support from the ALS Association.
Key figures
- Drug Name
- intranasal foralumab
- Phase Of Trial
- Phase 2a
- Randomization ratio
- 3:1
- Ms expanded access patients
- 14
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.